



**FOR IMMEDIATE RELEASE**

**For further information, contact:**

**Thomas R. Koning**

**Safety Syringes, Inc.**

**[www.safetysyringes.com](http://www.safetysyringes.com)**

**760.918.9908**

**Safety Syringes, Inc. Welcomes a Newly Launched Injectable Product Using the UltraSafe Passive® Delivery System**

*CARLSBAD, CA (June 10, 2007)*

Safety Syringes, Inc. welcomes another user of the UltraSafe Passive® Delivery System for their prefilled syringe presentation. Shire Pharmaceuticals has recently launched DYNEPO® epoetin delta in Germany with the UltraSafe Passive® Delivery System, completing the initial step of a larger-scale launch program planned for Europe over the coming several months.

DYNEPO® epoetin delta is a unique erythropoiesis-stimulating agent (ESA), as it is the only ESA produced in human cells. ESAs are agents used in the treatment of anemia to increase the production of red blood cells. DYNEPO is produced by activating the erythropoietin (EPO) gene in human cells. All other commercially available ESAs are presently made in animal cells.

DYNEPO® epoetin delta is packaged in prefilled syringes using the UltraSafe Passive® Delivery System. The syringe is designed for ease of use by both healthcare professionals and patients and features a needle safety system to reduce needlestick injuries. The needle is immediately protected after administration of the injection and activation of the safety mechanism requires no action by the user.

“We congratulate Shire on the ongoing launch of DYNEPO® and are proud to be the chosen drug delivery system,” stated Christer Andreasson, Safety Syringes, Inc.’s CEO. “The UltraSafe Passive® Delivery System has also proven to be widely preferred by clinicians as a delivery system for injectable medications.”

**###**

**Safety Syringes, Inc.**

Founded in 1991, Safety Syringes, Inc. is a global market leader for drug delivery systems for prefilled glass syringes. The UltraSafe Passive® Delivery System has been marketed since 2001. Several U.S. and international patents protect all products developed and marketed by Safety Syringes, Inc.

Designed to ensure the ultimate in user preference, compliance and protection, the UltraSafe Passive® Delivery System is intended for unit dose, prefilled glass syringe presentations. The easy-to-use, intuitive and innovative system provides an optimal drug delivery system with the preferred passive activation method.

DYNEPO is a registered trademark of Aventis Pharma

UltraSafe Passive is a registered trademark of Safety Syringes, Inc.